Glossary

American Depositary Share; one ADS is equivalent to one ordinary share

AIHA

Autoimmune hemolytic anemia, a rare autoimmune disease in which the immune system destroys red blood cells

B cell maturation antigen, a protein target involved in immune disease biology

Bispecific construct targeting BCMA and CD3 to engage T-cells

Cold agglutinin disease, a rare autoimmune hemolytic anemia

Financial investments and cash and cash equivalents available to the company

FDA designation intended to facilitate development and expedite review of therapies for serious conditions

U.S. Food and Drug Administration

Phase 2 study with GLPG3667 in patients with systemic lupus erythematosus

Phase 2 study with GLPG3667 in patients with dermatomyositis

Investigational BCMAxCD3 T-cell engager being developed for autoimmune diseases

TYK2 inhibitor evaluated in dermatomyositis and systemic lupus erythematosus

Immune thrombocytopenia, an autoimmune disease characterized by low platelet counts

License and Collaboration Agreement governing development and commercialization rights

Option, License and Collaboration Agreement

Regulatory designation granted to therapies intended for rare diseases

Rare autoimmune blistering disease affecting skin and mucous membranes

Clinical development stage evaluating safety and early activity in patients

Clinical development stage evaluating efficacy, safety and dose selection

Program under which a company buys back its own shares

Chronic autoimmune disease affecting moisture-producing glands

Autoimmune disease affecting multiple organs and tissues

Engineered therapy designed to redirect T cells toward target cells

Tyrosine kinase 2, an intracellular signaling protein involved in immune responses